1-8 of 8
James A Reeves
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

John M. Burke, Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A Reeves, Parameswaran Venugopal, Tomasz Wróbel, Don Stevens, John M. Pagel, Jerome Goldschmidt, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nilanjan Ghosh
Journal: Blood
Blood (2021) 138 (Supplement 1): 527.
https://doi.org/10.1182/blood-2021-151054
Published: 2021
Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Clinical Trials & Observations
Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, Kanti R. Rai, James A. Reeves, Bruce D. Cheson, Paul M. Barr, Suman Kambhampati, Frederick Lansigan, Jeffrey J. Pu, Alan P. Skarbnik, Lindsey Roeker, Gustavo A. Fonseca, Andrea Sitlinger, Issam S. Hamadeh, Colleen Dorsey, Nicole LaRatta, Hanna Weissbrot, Eline T. Luning Prak, Patricia Tsao, Dana Paskalis, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jakub Svoboda, Danielle M. Brander
Journal: Blood
Blood (2021) 137 (20): 2817–2826.
https://doi.org/10.1182/blood.2020007376
Published: 2021
Includes: Supplemental data
Journal Articles

Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Pier Luigi Zinzani, MD, Felipe Samaniego, MD, Wojciech Jurczak, MD PhD, Nilanjan Ghosh, MD PhD, Enrico Derenzini, MD PhD, James A Reeves, MD, Wanda Knopinska-Posluszny, MD PhD, Chan Yoon Cheah, MBBS, Tycel J. Phillips, MD, Ewa Lech-Marańda, MD PhD, Bruce D. Cheson, MD, Paolo F Caimi, MD, Sebastian Grosicki, MD PhD, Lori A. Leslie, MD, Julio C. Chavez, MD, Gustavo A. Fonseca, MD, Sunil Babu, Daniel J. Hodson, MDPhD, Spencer H. Shao, MD, John M. Burke, MD, Jeff P Sharman, MD, Jennie Y. Law, MD, John M. Pagel, MDPhD, Owen A. O'Connor, MD PhD, Hari P. Miskin, MSc, Peter Sportelli, BS, Michael S. Weiss, Nathan H Fowler, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–35.
https://doi.org/10.1182/blood-2020-134851
Published: 2020
Journal Articles

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

John P. Leonard, MD, Kathryn Kolibaba, MD, James A. Reeves, MD, Anil Tulpule, MD, Ian W. Flinn, MD PhD, Tatjana Kolevska, MD, Robert Robles, MD, Christopher Flowers, MD, Robert Collins, MD, Nicholas J. DiBella, MD, Steven W. Papish, MD, Parameswaran Venugopal, MD, Andrew Horodner, MD, Amir Tabatabai, MD, Julio Hajdenberg, MD, George Mulligan, PhD, Rachel Neuwirth, PhD, Kaveri Suryanarayan, Dixie-Lee Esseltine, MD, Sven de Vos, MD PhD
Journal: Blood
Blood (2015) 126 (23): 811.
https://doi.org/10.1182/blood.V126.23.811.811
Published: 2015
Journal Articles

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Kevin Doner, MD, Ian W. Flinn, MD, PhD, Brian K. Ulrich, MD, Stephen J. Noga, MD, PhD, Naveed M. Chowhan, MD, Steven W. Papish, MD, Tallat Mahmood, MD, James A Reeves, MD, Nicholas J. Di Bella, MD, Gerald J. Robbins, MD, Radhakrishnan Ramchandren, MD, Sein Aung, MD, William Lawler, MD, Sudha Parasuraman, MD, Maria M. Corvez, BA, George Mulligan, PhD, John P. Leonard, MD
Journal: Blood
Blood (2010) 116 (21): 1792.
https://doi.org/10.1182/blood.V116.21.1792.1792
Published: 2010
Journal Articles

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert M. Rifkin, MD, Nashat Y Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf A Gaffar, MD, Thomas A. Warr, MD, Rachel Neuwirth, MS, Deyanira Corzo, MD, James A Reeves, MD
Journal: Blood
Blood (2010) 116 (21): 619.
https://doi.org/10.1182/blood.V116.21.619.619
Published: 2010
Journal Articles

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert M. Rifkin, MD, Nashat Y Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf A Gaffar, MD, Thomas A. Warr, MD, Rachel Neuwirth, MS, Deyanira Corzo, MD, James A Reeves, MD
Journal: Blood
Blood (2010) 116 (21): 3026.
https://doi.org/10.1182/blood.V116.21.3026.3026
Published: 2010
Journal Articles

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Clinical Trials & Observations
Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter T. Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah Thomas, Robert D. Knight, Michele Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List
Journal: Blood
Blood (2008) 111 (1): 86–93.
https://doi.org/10.1182/blood-2007-01-068833
Published: 2008
Includes: Supplemental data